Abstract 247P
Background
Adenocarcinoma is an uncommon histologic variant and accounts for 0.5-2% of bladder cancers in the United States. Due to its rarity, there is limited data in the literature specifically focused on bladder adenocarcinoma treatment. So, the aim of this study is focused on evaluating the impact of chemoradiotherapy compared to multiple treatment modalities on the survival of patients with primary bladder adenocarcinoma.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Program 17 registries database was utilized to identify primary bladder adenocarcinoma cases from (2000-2020). The disease stages and sociodemographic data were collected. The patients were subgrouped according to the treatment modality: primary chemotherapy, surgery only, adjuvant chemotherapy, adjuvant radiotherapy, and adjuvant chemoradiotherapy. SPSS Version 23 was used for data analysis. log-rank Kaplan-Meir curve was used for survival analysis.
Results
A total of 2500 cases of bladder adenocarcinoma were identified. Overall, the 5-year relative survival was 43.1%. With multiple treatment options, we found surgery with no systemic therapy had a better survival outcome (47.4%) compared to adjuvant chemotherapy (38%), adjuvant chemoradiotherapy (31.4), adjuvant radiotherapy (21.5%), and least primary chemotherapy (4.9%) (P <0.001). In the group that had surgical management with no systemic therapy, the localized stage had significantly improved survival compared to the regional and distant spread (62%, 40%, and 10.8%, respectively; P <0.001).
Conclusions
This study provides a comprehensive evaluation of multiple treatment modalities, and the results highlight surgery with no systemic therapy as the modality of choice for improved survival outcome. This eliminates the burden of adjuvant therapy with unfavorable side effects. However, few selected patients may use chemo(radio)therapy with special considerations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract